The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study-Reference-Cited by-同舟云学术

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

Published:2015-03 Issue:3 Volume:16 Page:293-300
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ko Jenny J,Xie Wanling,Kroeger Nils,Lee Jae-lyun,Rini Brian I,Knox Jennifer J,Bjarnason Georg A,Srinivas Sandy,Pal Sumanta K,Yuasa Takeshi,Smoragiewicz Martin,Donskov Frede,Kanesvaran Ravindran,Wood Lori,Ernst D Scott,Agarwal Neeraj,Vaishampayan Ulka N,Rha Sun-young,Choueiri Toni K,Heng Daniel Y C

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Motzer;Lancet Oncol,2013

2. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008

3. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update;Sternberg;Eur J Cancer,2013

4. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma;Hutson;J Clin Oncol,2014

5. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2;Soerensen;Eur J Cancer,2014

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors;Cellular Oncology;2024-09-02

3. Cost-Effectiveness Analysis Comparing Biopsy in Advance of Ablation with Concurrent Biopsy and Ablation for Small Renal Masses Measuring 1–3 cm;Journal of Vascular and Interventional Radiology;2024-09

4. [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial;The Lancet Oncology;2024-09

5. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study;The Lancet;2024-09